Relmada Therapeutics Yönetim
Yönetim kriter kontrolleri 2/4
Relmada Therapeutics CEO'su Sergio Traversa, Apr2012 tarihinde atandı, in görev süresi 12.58 yıldır. in toplam yıllık tazminatı $ 4.78M olup, şirket hissesi ve opsiyonları dahil olmak üzere 14.7% maaş ve 85.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.27% ine doğrudan sahiptir ve bu hisseler $ 1.31M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.8 yıl ve 4.8 yıldır.
Anahtar bilgiler
Sergio Traversa
İcra Kurulu Başkanı
US$4.8m
Toplam tazminat
| CEO maaş yüzdesi | 14.7% |
| CEO görev süresi | 12.6yrs |
| CEO sahipliği | 1.3% |
| Yönetim ortalama görev süresi | 4.8yrs |
| Yönetim Kurulu ortalama görev süresi | 4.8yrs |
Son yönetim güncellemeleri
Recent updates
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
Mar 21Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 13
Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark
Jan 14Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Dec 04Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Aug 29We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
May 07We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Dec 15Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure
Oct 14Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up
Sep 14Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression
Aug 09We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely
Jul 14Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Feb 264 Clinical Catalysts On Tap For Relmada In 2022
Jan 28Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Nov 04Our First Look At Relmada Therapeutics
Jun 28We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Jun 28Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 09What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?
Jan 15
Enrollment underway in Relmada Therapeutics' late-stage depression study with REL-1017
Dec 07Relmada Therapeutics (RLMD) Investor Presentation - Slideshow
Dec 02Relmada Therapeutics (RLMD) Investor Presentation - Slideshow
Nov 16CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$87m |
| Mar 31 2024 | n/a | n/a | -US$94m |
| Dec 31 2023 | US$5m | US$701k | -US$99m |
| Sep 30 2023 | n/a | n/a | -US$112m |
| Jun 30 2023 | n/a | n/a | -US$129m |
| Mar 31 2023 | n/a | n/a | -US$144m |
| Dec 31 2022 | US$3m | US$668k | -US$157m |
| Sep 30 2022 | n/a | n/a | -US$153m |
| Jun 30 2022 | n/a | n/a | -US$157m |
| Mar 31 2022 | n/a | n/a | -US$143m |
| Dec 31 2021 | US$36m | US$630k | -US$126m |
| Sep 30 2021 | n/a | n/a | -US$112m |
| Jun 30 2021 | n/a | n/a | -US$86m |
| Mar 31 2021 | n/a | n/a | -US$71m |
| Dec 31 2020 | US$900k | US$600k | -US$59m |
| Sep 30 2020 | n/a | n/a | -US$43m |
| Jun 30 2020 | n/a | n/a | -US$30m |
| Mar 31 2020 | n/a | n/a | -US$23m |
| Dec 31 2019 | US$16m | US$214k | -US$15m |
| Sep 30 2019 | n/a | n/a | -US$18m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$17m |
| Dec 31 2018 | n/a | n/a | -US$17m |
| Sep 30 2018 | n/a | n/a | -US$11m |
| Jun 30 2018 | US$975k | US$376k | -US$9m |
Tazminat ve Piyasa: Sergio 'nin toplam tazminatı ($USD 4.78M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 651.15K ).
Tazminat ve Kazançlar: Sergio şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Sergio Traversa (64 yo)
12.6yrs
Görev süresi
US$4,778,944
Tazminat
Dr. Sergio Traversa, PharmD, MBA has been the Chief Executive Officer and a Director of Relmada Therapeutics, Inc. since April 18, 2012. Dr. Traversa served as Interim Chief Financial Officer at Relmada Th...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 12.6yrs | US$4.78m | 1.27% $ 1.3m | |
| Chief Financial Officer | 4.8yrs | US$2.34m | 0.29% $ 300.3k | |
| Chief Accounting & Compliance Officer | 4.8yrs | US$2.33m | 0.13% $ 132.5k | |
| Chief Scientific Officer | 4.1yrs | Veri yok | Veri yok | |
| VP & Head of Clinical Operations | 5.6yrs | Veri yok | Veri yok | |
| Chief Clinical Officer | 4.1yrs | Veri yok | Veri yok | |
| Head of Commercial | 2.3yrs | Veri yok | Veri yok | |
| Senior Clinical Development Advisor | no data | Veri yok | Veri yok | |
| Consultant | 7.6yrs | Veri yok | Veri yok |
4.8yrs
Ortalama Görev Süresi
63yo
Ortalama Yaş
Deneyimli Yönetim: RLMD 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 12.6yrs | US$4.78m | 1.27% $ 1.3m | |
| Chief Financial Officer | 4.8yrs | US$2.34m | 0.29% $ 300.3k | |
| Independent Chairman of the Board | 9.3yrs | US$674.90k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.8yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 7.4yrs | Veri yok | Veri yok | |
| Independent Director | 1.8yrs | US$1.33m | 0% $ 0 | |
| Director | 9yrs | US$1.67m | 0.70% $ 721.8k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 4.9yrs | US$604.77k | Veri yok | |
| Member of Scientific Advisory Board | 4.8yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 4.8yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 4.8yrs | Veri yok | Veri yok |
4.8yrs
Ortalama Görev Süresi
62.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: RLMD 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).